DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for facioscapulohumeral muscular dystrophy — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFacioscapulohumeral muscular dystrophy maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for facioscapulohumeral muscular dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FSHD region gene 1 (FRG1) — FRG1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ihpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZYM · 3.4 Å · ligand INOSITOL HEXAKISPHOSPHATE (IHP). Experimental structure, not a prediction.
What the evidence adds up to
Facioscapulohumeral muscular dystrophy is the third most common inherited muscular dystrophy in adults, after Duchenne dystrophy and myotonic dystrophy. By 1997 a consensus had been reached that FSHD results from a toxic gain-of-function caused by de-repression of the DUX4 gene, which is not normally expressed in skeletal muscle. Despite this clear therapeutic target, the exact mechanisms that lead to atrophy and weakness secondary to the genetic defect were still not understood as of 2007. The molecular signalling pathways remained poorly studied as of 2017.
The 1997 review noted that a targeted approach to treatment was possible for the first time, and that interest in drug development was buoyed by recent therapeutic successes in other neuromuscular diseases. The 2007 article aimed to increase awareness of FSHD among clinicians and to discuss opportunities for research, but provided no data on any drug tested in patients. The 2017 article reconstructed the molecular signalling pathway from literature data but did not report any clinical trial results.
No concrete numbers for survival, response rates, or sample sizes appear in any of these abstracts. No drug is named, no intervention is tested, and no efficacy data are presented. What is still missing are completed clinical trials with measurable outcomes, patient stratification based on DUX4 expression, and the funding needed to move from a known genetic target to a tested therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Physical Therapy · 2007 · 73 citations · open access
Facioscapulohumeral Dystrophy
AbstractFacioscapulohumeral dystrophy (FSHD) is the third most common inherited muscular dystrophy after Duchenne dystrophy and myotonic dystrophy. Over the last decade, major advances have occurred in the understanding of the genetics of this disorder. Despite these advances, the exact mechanisms that lead to atrophy and weakness secondary to the genetic defect are still not understood. The purposes of this article are to increase awareness of FSHD among clinicians; to provide an update regarding the genetics, clinical features, natural history, and current management of FSHD; and to discuss opportunities for research.
Archives of Otolaryngology - Head and Neck Surgery · 1984 · 35 citations
Facioscapulohumeral Muscular Dystrophy and Accompanying Hearing Loss
AbstractFacioscapulohumeral (FSH) muscular dystrophy (MD) is an autosomal dominant condition marked by muscle weakness primarily in the face, shoulder girdle, and legs. Intelligence and life span are normal and the spectrum of disability is broad. Flaccid dysarthria results from the facial muscle paralysis. A pair of siblings had FSH MD that was accompanied by the unusual finding of sensorineural hearing loss. Speech and audiologic aspects are presented and etiologic explanations are suggested. Careful audiologic evaluation of all patients with FSH MD is advised so that sensorineural hearing loss can be ruled out.
New England Journal of Medicine · 1965 · 24 citations
Ineffective Treatment of Muscular Dystrophy with an Anabolic Steroid and Other Measures
AbstractTHROUGHOUT the years many agents have been tested for their therapeutic benefit in muscular dystrophy, a relentlessly progressive disease. Eventually, all have been found to be ineffective after careful evaluation, including a variety of anabolic hormones.1 2 3 4 5 6 7 8 More recently Dowben9 has presented preliminary evidence that patients with muscular dystrophy showed significant "improvement" when treated by a program consisting of the anabolic steroid, 1-methyl-Δ1 androstenolone acetate,ǁ digitoxin and exercise.The purpose of this report is to re-evaluate such a therapeutic program in muscular dystrophy when the drugs are used singly, in combination and with or without exercise. Objective serial measurements were made . . .
Journal of Neurology & Stroke · 2017 · 2 citations · open access
Facioscapulohumeral Muscular Dystrophy: The Molecular Signaling Pathway
AbstractFacioscapulohumeral muscular dystrophy (FSHD) is the third most common myopathy found in adults. It is a unique genetic disease because the activation of the normally inactive gene leads to the development of pathology. The molecular mechanisms and the signaling pathways remain poorly studied so far. Here the literature data is summarized and the molecular signaling pathway of FSHD is reconstructed.
Journal of Medical and Scientific Research · 2019 · 1 citations · open access
Climb 6-hills in a coat with Popeye, you shall find facioscapulohumeral dystrophy - Going from phenotype to genotype
AbstractFacioscapulohumeral dystrophy (FSHD), is a rare muscle disease in clinical practice. Identifying the condition with its classic clinical signs helps in better managing patients early. This report is to shed light upon this condition and signs associated with it. We also try to elaborate a few genetic aspects and their pathogenetic mechanisms in the review.
Dialnet (Universidad de la Rioja) · 1997 · 0 citations
Contra el monopolio de Dios: reflexiones de un buscador descreído
AbstractFacioscapulohumeral muscular dystrophy (FSHD) is one of the most common muscular dystrophies. Over the last decade, a consensus was reached regarding the underlying cause of FSHD allowing-for the first time-a targeted approach to treatment. FSHD is the result of a toxic gain-of-function from de-repression of the DUX4 gene, a gene not normally expressed in skeletal muscle. With a clear therapeutic target, there is increasing interest in drug development for FSHD, an interest buoyed by the recent therapeutic successes in other neuromuscular diseases. Herein, we review the underlying disease mechanism, potential therapeutic approaches as well as the state of trial readiness in the planning and execution of future clinical trials in FSHD.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
